ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 057,80
-0,92%
Dow Jones
38 813,21
-0,66%
DAX
18 677,87
-0,45%
Brent Oil
84,235
1,68%
Bitcoin
68 368,38
-1,48%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aligos Therapeutics Inc (ALGS)

  7. Aligos Therapeutics Inc (ALGS) Actualités

ALGS

Aligos Therapeutics (ALGS)

Aligos Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALGS
DateHeureSourceTitreSymboleSociété
22/05/202422h05GlobeNewswire Inc.Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024NASDAQ:ALGSAligos Therapeutics Inc
22/05/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
21/05/202414h00GlobeNewswire Inc.Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASHNASDAQ:ALGSAligos Therapeutics Inc
07/05/202422h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALGSAligos Therapeutics Inc
07/05/202422h05GlobeNewswire Inc.Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial ResultsNASDAQ:ALGSAligos Therapeutics Inc
30/04/202422h05GlobeNewswire Inc.Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024NASDAQ:ALGSAligos Therapeutics Inc
25/04/202422h05GlobeNewswire Inc.Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 StudyNASDAQ:ALGSAligos Therapeutics Inc
25/04/202414h00GlobeNewswire Inc.Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MDNASDAQ:ALGSAligos Therapeutics Inc
09/04/202414h00GlobeNewswire Inc.Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024NASDAQ:ALGSAligos Therapeutics Inc
03/04/202414h00GlobeNewswire Inc.Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH SubjectsNASDAQ:ALGSAligos Therapeutics Inc
27/03/202413h00GlobeNewswire Inc.Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 StudiesNASDAQ:ALGSAligos Therapeutics Inc
18/03/202413h00GlobeNewswire Inc.Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH SubjectsNASDAQ:ALGSAligos Therapeutics Inc
12/03/202421h05GlobeNewswire Inc.Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALGSAligos Therapeutics Inc
05/03/202422h05GlobeNewswire Inc.Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024NASDAQ:ALGSAligos Therapeutics Inc
04/03/202423h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
26/02/202414h00GlobeNewswire Inc.Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:ALGSAligos Therapeutics Inc
20/02/202414h00GlobeNewswire Inc.Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024NASDAQ:ALGSAligos Therapeutics Inc
13/02/202414h00GlobeNewswire Inc.Aligos Therapeutics Strengthens Finance Leadership Team with Two New AppointmentsNASDAQ:ALGSAligos Therapeutics Inc
30/01/202413h04Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:ALGSAligos Therapeutics Inc
25/01/202412h12Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:ALGSAligos Therapeutics Inc
28/11/202322h01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ALGSAligos Therapeutics Inc
17/11/202322h38Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALGSAligos Therapeutics Inc
07/11/202318h03Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ALGSAligos Therapeutics Inc
02/11/202321h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALGSAligos Therapeutics Inc
02/06/202322h06Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)NASDAQ:ALGSAligos Therapeutics Inc
04/05/202322h22Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALGSAligos Therapeutics Inc
04/05/202322h08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALGSAligos Therapeutics Inc
28/04/202323h08Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ALGSAligos Therapeutics Inc
28/04/202323h00Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ALGSAligos Therapeutics Inc
17/03/202321h13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALGSAligos Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALGS

Dernières Valeurs Consultées

BIT
I06996
Intesa Sanpaolo
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés